Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.Xianjun Yu, Hui Zhou, Jinbo Yue et al.|Journal of Clinical Oncology|2025Cited by 10